Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Simulations Plus Sets Date for 2nd Quarter 2020 Earnings Release and Conference Call

BusinessWire_EN 
0 0 02.04.20
Simulations Plus Sets Date for 2nd Quarter 2020 Earnings Release and Conference Call
 

Simulations Plus, Inc. (Nasdaq: SLP) announced today that it expects to file its quarterly report on Form 10-Q for the second quarter of its 2020 fiscal year, the period ended February 29, 2020, on Thursday, April 9, 2020.

The Company will host a conference call on April 9, 2020, at 4:15 p.m. Eastern Time. All interested parties are invited to join the call by registering here. On registering, you will receive a confirmation e-mail with instructions for joining the call. Please dial in five to ten minutes prior to the scheduled start time. For listen-only mode, you may dial (914) 614-3221, and enter access code 938-770-331. A replay will be available at the Simulations Plus website following the call.

About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical and biotechnology agents. Our software is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies and regulatory agencies worldwide. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into our software have made us the leading software provider for physiologically based pharmacokinetic modeling and simulation. For more information, visit our website at www.simulations-plus.com.

Follow us on Twitter | LinkedIn | YouTube

View source version on businesswire.com: https://www.businesswire.com/news/home/20200402005265/en/

Simulations Plus Stock

€34.00
4.290%
A very strong showing by Simulations Plus today, with an increase of €1.40 (4.290%) compared to yesterday's price.
The community is currently still undecided about Simulations Plus with 1 Buy predictions and 0 Sell predictions.
With a target price of 46 € there is a positive potential of 35.29% for Simulations Plus compared to the current price of 34.0 €.
Show more
Like: 0
Share
BusinessWire_EN 
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Legal notice

Comments

Not a member yet? Sign up for free!